Fulcrum Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FULC Nasdaq 2836 www.fulcrumtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 8th, 2026 2:30 pm
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... - Apr 28th, 2026 1:02 am
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary - Apr 27th, 2026 10:46 am
Fulcrum Therapeutics Q1 Earnings Call Highlights - Apr 27th, 2026 9:45 am
Fulcrum (FULC) Q1 2026 Earnings Transcript - Apr 27th, 2026 9:41 am
Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations - Apr 27th, 2026 9:08 am
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 - Apr 27th, 2026 5:00 am
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors - Apr 27th, 2026 4:55 am
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET - Apr 20th, 2026 6:00 am
Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher - Mar 31st, 2026 2:02 pm
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - Mar 19th, 2026 6:00 am
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - Mar 16th, 2026 7:33 pm
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - Mar 3rd, 2026 6:30 am
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Feb 25th, 2026 8:27 am
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Feb 24th, 2026 6:05 pm
Fulcrum Therapeutics Q4 Earnings Call Highlights - Feb 24th, 2026 9:47 am
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - Feb 24th, 2026 5:01 am
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Feb 24th, 2026 5:00 am
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Feb 17th, 2026 6:00 am
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? - Feb 12th, 2026 7:55 am